Selbyville, Delaware, Oct. 01, 2024 (GLOBE NEWSWIRE) --
Immune Checkpoint Inhibitors Market size reached USD 47.4 billion in 2023 and is projected to register a CAGR of 16.7% from 2024 to 2032 driven by the rising global cancer prevalence and demand for advanced, personalized therapies.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/10860
Immune checkpoint inhibitors enhance the immune system's ability to target cancer cells, showing effectiveness against melanoma, lung cancer, and renal cell carcinoma. Extensive clinical trials, favorable regulatory approvals, and integration into treatment protocols support market expansion. Increased investments in oncology research and a strong pipeline of new inhibitors sustain market progression. For instance, in July 2021, the Rankin government invested USD 18 million in cancer therapies, including immune checkpoint inhibitors. In 2023, the Cancer Research Institute allocated USD 28 million for cancer immunotherapy research. Such support from governmental and organizational entities is crucial for industry gains.
The overall immune checkpoint inhibitors market is classified based on the type, application, end-use, and region.
Immune checkpoint inhibitors block proteins known as checkpoints, enhancing immune cells' ability to attack cancer cells. The market is categorized by type: PD-L1, CTLA-4, PD-1, and others. The PD-1 segment dominated in 2023 with USD 34.7 billion. PD-1 inhibitors, like nivolumab and pembrolizumab, show impressive efficacy across various cancers, including non-small cell lung cancer, melanoma, and renal cell carcinoma. Robust clinical outcomes and growing adoption within oncology practices reinforce the leading market position of PD-1 inhibitors.
The immune checkpoint inhibitors market is segmented by application into melanoma, breast cancer, lung cancer, bladder cancer, Hodgkin lymphoma, cervical cancer, colorectal cancer, and others. In 2023, lung cancer led with a 25.1% share. Lung cancer's significant burden and the proven efficacy of these therapies enhance patient outcomes. In 2023, the U.S. saw 238,340 new lung cancer diagnoses, with approximately 127,070 fatalities. Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have shown success in treating non-small cell lung cancer (NSCLC). Ongoing research and clinical trials are broadening the application of these inhibitors across various lung cancer stages.
In 2023, North America held a USD 22.9 billion share of the immune checkpoint inhibitors market, with a projected CAGR of 16.8% from 2024 to 2032. The presence of leading pharmaceutical companies and a favorable regulatory landscape bolster the North American market. The American Cancer Society estimates around 2,170,450 new cancer cases in the U.S. and Canada in 2024, highlighting the demand for advanced cancer therapies. Additionally, increasing government funding for cancer research and treatment is further driving the business development in the region.
Request for Report Customization @ https://www.gminsights.com/roc/10860
Major players in immune checkpoint inhibitors market include AstraZeneca PLC, BeiGene, Ltd., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Incyte Corporation, Immutep Limited, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Shanghai Junshi Biosciences Co., Ltd. among others.
Partial Table of Contents (ToC) of the report:
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising cancer incidence across the world
3.2.1.2 Ongoing research and development in immunotherapy
3.2.1.3 Favorable regulatory environment
3.2.1.4 Increasing investments and partnerships
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Adverse side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Browse more disease specific drugs industry reports @ https://www.gminsights.com/industry-reports/disease-specific-drugs/82
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
